DOCSLIB.ORG

Transcriptional Regulation, Role in Inflammation and Potential Pharmacological Implications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transcriptional Regulation, Role in Inflammation and Potential Pharmacological Implications UNIVERSITA’ DEGLI STUDI DI MILANO Dipartimento di Biotecnologie Mediche e Medicina Traslazionale Scuola di dottorato in Medicina Sperimentale e Biotecnologie Mediche Ciclo XXIX THE HUMAN-RESTRICTED DUPLICATED FORM OF THE α7 NICOTINIC ACETYLCHOLINE RECEPTOR, CHRFAM7A: TRANSCRIPTIONAL REGULATION, ROLE IN INFLAMMATION AND POTENTIAL PHARMACOLOGICAL IMPLICATIONS. Settore disciplinare: Bio/14 Tesi di dottorato di: Annalisa Maroli Relatore: Prof.ssa Grazia Pietrini Coordinatore: Prof. Massimo Locati Anno accademico: 2016-2017 1 2 Contents Abstract ................................................................................................................................. 5 1. Introduction ................................................................................................................... 7 1.1. Inflammation........................................................................................................... 7 1.1.1. Acute inflammation ......................................................................................... 7 1.1.2. Molecular mechanisms of acute inflammation ............................................... 9 1.1.3. Resolution of acute inflammation ................................................................. 13 1.1.4. Chronic inflammation .................................................................................... 14 1.2. The Cholinergic Anti-Inflammatory Pathway........................................................ 14 1.3. The α7 nicotinic acetylcholine receptor ............................................................... 18 1.3.1. The CHRNA7 gene .......................................................................................... 21 1.3.2. α7 nicotinic acetylcholine protein in the nervous system ............................ 23 1.3.3. Function of the α7 nicotinic acetylcholine receptor in the immune system 24 1.3.4. α7nAChR-related pathologies ....................................................................... 26 1.3.5. α7nAChR involvement in AD therapy: the case of Donepezil ....................... 31 1.4. The CHRFAM7A gene ............................................................................................ 33 1.4.1. The CHRFAM7A locus .................................................................................... 33 1.4.2. The CHRFAM7A transcript ............................................................................. 35 1.4.3. The α7dup protein ......................................................................................... 38 1.4.4. CHRFAM7A involvement in human disease .................................................. 44 2. Aim of the project ........................................................................................................ 48 3. Materials and Methods ............................................................................................... 50 3.1. Cell Lines ............................................................................................................... 50 3.2. Cell treatment ....................................................................................................... 50 3.3. 5’ RACE .................................................................................................................. 51 3.4. Total RNA Extraction and Reverse Transcription .................................................. 52 3.5. Standard PCR protocol using GoTaq Flexi (Promega) ........................................... 52 3.6. High Fidelity PCR using Expand High Fidelity PCR System (Roche) ...................... 53 3.7. Quantitative Real-Time PCR .................................................................................. 53 3.8. Absolute quantification by Real-Time RT-PCR ...................................................... 54 3.9. Plasmid vectors ..................................................................................................... 55 3 3.10. Transient transfection and luciferase assay ...................................................... 60 3.11. Data analysis ...................................................................................................... 60 3.12. Chromatin Immunoprecipitation ...................................................................... 61 3.13. Electrophoresis Mobility Shift Assay ................................................................. 62 3.14. Human biological samples ................................................................................ 63 4. Results.......................................................................................................................... 65 4.1. Characterization of CHRFAM7A transcriptional regulation .................................. 65 4.1.1. Identification of the CHRFAM7A regulatory region ...................................... 65 4.1.2. Identification of multiple Transcription Start Sites (TSS) in monocytic cell line, primary human macrophages and neuroblastoma cell model ........................... 67 4.1.3. Functional analysis of the CHRFAM7A regulatory sequence in THP-1 and SH- SY5Y cell line ................................................................................................................ 73 4.1.4. The CHRFAM7A Intron 4 reduces the transcriptional activity in THP-1 but not in SH-SY5Y cell model .................................................................................................. 77 4.1.5. Identification of a novel CHRFAM7A Transcription Start Site in intron 5 ..... 81 4.1.6. LPS treatment causes chromatin remodelling at the CHRFAM7A promoter 84 4.1.7. LPS treatment decreases CHRFAM7A promoter activity .............................. 87 4.1.8. Summary ........................................................................................................ 90 4.2. CHRFAM7A as pharmacological target in Alzheimer’s disease: a report of Donepezil effect ............................................................................................................... 90 4.2.1. CHRNA7 and CHRFAM7A expression levels in hippocampus of AD patients 90 4.2.2. CHRNA7 and CHRFAM7A expression level in human PBMCs of AD untreated and Donepezil treated patients ................................................................................... 93 4.2.3. Donepezil up-regulates CHRFAM7A transcript in THP-1 cell model ............. 94 4.2.4. Donepezil treatment on human primary macrophages modulates CHRNA7 and CHRFAM7A transcript ......................................................................................... 102 4.2.5. Donepezil treatment up-regulates CHRFAM7A and down-regulates CHRNA7 gene in SH-SY5Y cell model ....................................................................................... 105 4.2.6. Summary ...................................................................................................... 106 5. Discussion .................................................................................................................. 108 6. Conclusions ................................................................................................................ 121 Acknowledgment ............................................................................................................... 123 Bibliography ....................................................................................................................... 124 4 Abstract The α7 nicotine acetylcholine receptor (α7nAChR, CHRNA7) is a homo-pentameric ligand-gated ion channel widely expressed in the Central Nervous System (CNS). Recent evidence has demonstrated its expression also in non-neuronal tissues, including monocytes and macrophages, where it mediates the Cholinergic Anti-Inflammatory Pathway, a neuronal reflex providing the central control of systemic inflammation. Recently, the human-restricted duplicated gene of the α7nAChR, called CHRFAM7A (α7dup) has been discovered. It is the product of the partial duplication and fusion of exon 5-10 of CHRNA7 gene with the novel exons D, C, B and A belonging to the FAM7A gene, of unknown function. The CHRFAM7A gene is expressed in human immune cells and in the CNS and is translated into two proteins, of 45 kDa and 36 kDa, which are the result of alternative splicing. The α7dup protein assembles with the α7 conventional subunits and exerts a dominant negative regulation on the α7nAChR function. The importance of the α7dup protein in the human inflammatory process has been confirmed by the demonstration of its responsiveness to pro-inflammatory stimuli: indeed, the Lipopolysaccharide (LPS) treatment of THP-1 monocytic cells and of human primary monocytes and macrophages down-regulates CHRFAM7A transcript and protein through a transcriptional mechanism reliant on the NF-κB transcription factor. Moreover, unpublished data demonstrated that LPS has the opposite effect on the α7 transcript in monocytes and macrophages, leading to CHRNA7 up-regulation. In this study, we have investigated the transcriptional mechanisms leading to CHRFAM7A expression in the THP-1 monocytic cells and in neuroblastoma SH-SY5Y cells and we demonstrate that the CHRFAM7A gene is endowed with several complex transcriptional mechanisms leading to fine expression modulation, including the presence of alternative and tissue-specific Transcription Start Site (TSS), alternative splicing mechanism, tissue-specific transcriptional elements and intronic silencer elements. Moreover, we demonstrated that the CHRFAM7A down-regulation exerted by LPS involve the chromatin remodeling
Load more

Recommended publications
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • Nicotine Dependece
    Alma Mater Studiorum – Università di Bologna DOTTORATO DI RICERCA IN Biologia Cellulare e Molecolare Ciclo XXX Settore Concorsuale: 05/I1 Settore Scientifico Disciplinare: BIO/18 GENETICA Investigation of genetic risk variants for nicotine dependence and cluster headache Presentata da: Cinzia Cameli Coordinatore Dottorato Supervisore Prof. Giovanni Capranico Prof.ssa Elena Maestrini Co-supervisore Dott.ssa Elena Bacchelli Esame finale anno 2018 TABLE OF CONTENTS ABSTRACT......................................................................................................................... 4 INTRODUCTION ................................................................................................................ 6 CHAPTER 1 Nicotine dependence ...................................................................................... 6 1.1 Biological mechanisms ............................................................................................................ 6 1.2 Nicotinic acetylcholine receptors ............................................................................................ 8 1.2.1 Protein structure ............................................................................................................. 8 1.2.2 Localization and function of neuronal nAChRs ............................................................. 10 1.2.3 α7 nAChRs ..................................................................................................................... 12 1.3 The genetics of nicotine dependence ..................................................................................
    [Show full text]
  • Uniquely Human CHRFAM7A Gene Increases the Hematopoietic Stem Cell Reservoir in Mice and Amplifies Their Inflammatory Response
    UC San Diego UC San Diego Previously Published Works Title Uniquely human CHRFAM7A gene increases the hematopoietic stem cell reservoir in mice and amplifies their inflammatory response. Permalink https://escholarship.org/uc/item/6b96b0tv Journal Proceedings of the National Academy of Sciences of the United States of America, 116(16) ISSN 0027-8424 Authors Costantini, Todd W Chan, Theresa W Cohen, Olga et al. Publication Date 2019-04-03 DOI 10.1073/pnas.1821853116 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Uniquely human CHRFAM7A gene increases the hematopoietic stem cell reservoir in mice and amplifies their inflammatory response Todd W. Costantinia, Theresa W. Chana, Olga Cohena, Simone Langnessa, Sabrina Treadwella, Elliot Williamsa, Brian P. Eliceiria, and Andrew Bairda,1 aDepartment of Surgery, University of California, San Diego, La Jolla, CA 92093 Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved March 8, 2019 (received for review December 21, 2018) A subset of genes in the human genome are uniquely human and independently regulated by unique promoters that drive their differ- not found in other species. One example is CHRFAM7A, a dominant- ential expression (13, 14). Moreover, several genetic studies have tied the negative inhibitor of the antiinflammatory α7 nicotinic acetylcholine CHRFAM7A/CHRNA7 locus and a 2-bp mutation in CHRFAM7A receptor (α7nAChR/CHRNA7) that is also a neurotransmitter receptor on chromosome 15 to nicotine
    [Show full text]
  • Abstracts from the 51St European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 27:870–1041 https://doi.org/10.1038/s41431-019-0408-3 MEETING ABSTRACTS Abstracts from the 51st European Society of Human Genetics Conference: Electronic Posters © European Society of Human Genetics 2019 June 16–19, 2018, Fiera Milano Congressi, Milan Italy Sponsorship: Publication of this supplement was sponsored by the European Society of Human Genetics. All content was reviewed and approved by the ESHG Scientific Programme Committee, which held full responsibility for the abstract selections. Disclosure Information: In order to help readers form their own judgments of potential bias in published abstracts, authors are asked to declare any competing financial interests. Contributions of up to EUR 10 000.- (Ten thousand Euros, or equivalent value in kind) per year per company are considered "Modest". Contributions above EUR 10 000.- per year are considered "Significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal Genetics then compared this data to de novo cases where research based PO studies were completed (N=57) in NY. E-P01.01 Results: MFSIQ (66.4) for familial deletions was Parent of origin in familial 22q11.2 deletions impacts full statistically lower (p = .01) than for de novo deletions scale intelligence quotient scores (N=399, MFSIQ=76.2). MFSIQ for children with mater- nally inherited deletions (63.7) was statistically lower D. E. McGinn1,2, M. Unolt3,4, T. B. Crowley1, B. S. Emanuel1,5, (p = .03) than for paternally inherited deletions (72.0). As E. H. Zackai1,5, E. Moss1, B. Morrow6, B. Nowakowska7,J. compared with the NY cohort where the MFSIQ for Vermeesch8, A.
    [Show full text]
  • The Genetics of Bipolar Disorder
    Molecular Psychiatry (2008) 13, 742–771 & 2008 Nature Publishing Group All rights reserved 1359-4184/08 $30.00 www.nature.com/mp FEATURE REVIEW The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions A Serretti and L Mandelli Institute of Psychiatry, University of Bologna, Bologna, Italy Bipolar disorder (BP) is a complex disorder caused by a number of liability genes interacting with the environment. In recent years, a large number of linkage and association studies have been conducted producing an extremely large number of findings often not replicated or partially replicated. Further, results from linkage and association studies are not always easily comparable. Unfortunately, at present a comprehensive coverage of available evidence is still lacking. In the present paper, we summarized results obtained from both linkage and association studies in BP. Further, we indicated new potential interesting genes, located in genome ‘hot regions’ for BP and being expressed in the brain. We reviewed published studies on the subject till December 2007. We precisely localized regions where positive linkage has been found, by the NCBI Map viewer (http://www.ncbi.nlm.nih.gov/mapview/); further, we identified genes located in interesting areas and expressed in the brain, by the Entrez gene, Unigene databases (http://www.ncbi.nlm.nih.gov/entrez/) and Human Protein Reference Database (http://www.hprd.org); these genes could be of interest in future investigations. The review of association studies gave interesting results, as a number of genes seem to be definitively involved in BP, such as SLC6A4, TPH2, DRD4, SLC6A3, DAOA, DTNBP1, NRG1, DISC1 and BDNF.
    [Show full text]
  • UC Irvine UC Irvine Previously Published Works
    UC Irvine UC Irvine Previously Published Works Title Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Permalink https://escholarship.org/uc/item/0wh7t3r9 Journal PloS one, 7(12) ISSN 1932-6203 Authors Swaminathan, Shanker Huentelman, Matthew J Corneveaux, Jason J et al. Publication Date 2012 DOI 10.1371/journal.pone.0050640 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals Shanker Swaminathan1,2, Matthew J. Huentelman3,4, Jason J. Corneveaux3,4, Amanda J. Myers5,6, Kelley M. Faber2, Tatiana Foroud1,2,7, Richard Mayeux8, Li Shen1,7, Sungeun Kim1,7, Mari Turk3,4, John Hardy9, Eric M. Reiman3,4,10, Andrew J. Saykin1,2,7*, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the NIA-LOAD/NCRAD Family Study Group 1 Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 2 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 3 Neurogenomics Division, The Translational Genomics Research Institute (TGen), Phoenix, Arizona, United States of America, 4 The Arizona Alzheimer’s Consortium, Phoenix, Arizona, United States of America, 5 Departments of Psychiatry and Behavioral Sciences, and Human Genetics and Genomics, University of Miami, Miller School of Medicine, Miami, Florida, United States of America, 6 Johnnie B. Byrd Sr.
    [Show full text]
  • Uniquely Human CHRFAM7A Gene Increases the Hematopoietic Stem Cell Reservoir in Mice and Amplifies Their Inflammatory Response
    Uniquely human CHRFAM7A gene increases the hematopoietic stem cell reservoir in mice and amplifies their inflammatory response Todd W. Costantinia, Theresa W. Chana, Olga Cohena, Simone Langnessa, Sabrina Treadwella, Elliot Williamsa, Brian P. Eliceiria, and Andrew Bairda,1 aDepartment of Surgery, University of California, San Diego, La Jolla, CA 92093 Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved March 8, 2019 (received for review December 21, 2018) A subset of genes in the human genome are uniquely human and independently regulated by unique promoters that drive their differ- not found in other species. One example is CHRFAM7A, a dominant- ential expression (13, 14). Moreover, several genetic studies have tied the negative inhibitor of the antiinflammatory α7 nicotinic acetylcholine CHRFAM7A/CHRNA7 locus and a 2-bp mutation in CHRFAM7A receptor (α7nAChR/CHRNA7) that is also a neurotransmitter receptor on chromosome 15 to nicotine dependence, schizophrenia, cogni- linked to cognitive function, mental health, and neurodegenerative tive dysfunction, and bipolar and neurodegenerative disease (9, 10). disease. Here we show that CHRFAM7A blocks ligand binding to both Several recent studies have suggested that CHRFAM7A encodes a mouse and human α7nAChR, and hypothesized that CHRFAM7A- dominant-negative inhibitor of ligand binding to α7nAChR in vitro transgenic mice would allow us to study its biological significance in (15–18), which can also be observed at the neuromuscular junction of a tractable animal model of human inflammatory disease, namely transgenic mice (19). As such, CHRFAM7A has been implicated in SIRS, the systemic inflammatory response syndrome that accompanies the regulation of numerous α7nAChR-dependent antiinflammatory severe injury and sepsis.
    [Show full text]
  • Genetic Variation in CHRNA7 and CHRFAM7A Is Associated with Nicotine Dependence and Response to Varenicline Treatment
    European Journal of Human Genetics (2018) 26:1824–1831 https://doi.org/10.1038/s41431-018-0223-2 ARTICLE Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment 1 1 2 3 4 5,6 Cinzia Cameli ● Elena Bacchelli ● Maria De Paola ● Giuliano Giucastro ● Stefano Cifiello ● Ginetta Collo ● 2 2 1 7 Maria Michela Cainazzo ● Luigi Alberto Pini ● Elena Maestrini ● Michele Zoli Received: 26 January 2018 / Revised: 15 June 2018 / Accepted: 3 July 2018 / Published online: 8 August 2018 © European Society of Human Genetics 2018 Abstract The role of nicotinic acetylcholine receptors (nAChR) in nicotine dependence (ND) is well established; CHRNA7, encoding the α7 subunit, has a still uncertain role in ND, although it is implicated in a wide range of neuropsychiatric conditions. CHRFAM7A, a hybrid gene containing a partial duplication of CHRNA7, is possibly involved in modulating α7 nAChR function. The aim of this study was to investigate the role of CHRNA7 and CHRFAM7A genetic variants in ND and to test the hypothesis that α7 nAChR variation may modulate the efficacy of varenicline treatment in smoking cessation. We assessed CHRNA7 and CHRFAM7A copy number, CHRFAM7A exon 6 Δ2 bp polymorphism, and sequence variants in the CHRNA7 1234567890();,: 1234567890();,: proximal promoter in an Italian sample of 408 treatment-seeking smokers. We conducted case-control and quantitative association analyses using two smoking measures (cigarettes per day, CPD, and Fagerström Test for Nicotine Dependence, FTND). Next, driven by the hypothesis that varenicline may exert some of its therapeutic effects through activation of α7 nAChRs, we restricted the analysis to a subgroup of 142 smokers who received varenicline treatment.
    [Show full text]
  • Structure, Dynamics, and Ligand Recognition of Human-Specific CHRFAM7A (Dup7) Nicotinic Receptor Linked to Neuropsychiatric Diso
    International Journal of Molecular Sciences Article Structure, Dynamics, and Ligand Recognition of Human-Specific CHRFAM7A (Dupα7) Nicotinic Receptor Linked to Neuropsychiatric Disorders Danlin Liu 1,†, João V. de Souza 1,†, Ayaz Ahmad 1 and Agnieszka K. Bronowska 1,2,* 1 Chemistry—School of Natural and Environmental Sciences, Newcastle University, Newcastle NE1 7RU, UK; [email protected] (D.L.); [email protected] (J.V.d.S.); [email protected] (A.A.) 2 Newcastle University Centre for Cancer, Newcastle University, Newcastle NE1 7RU, UK * Correspondence: [email protected] † Equal contribution. Abstract: Cholinergic α7 nicotinic receptors encoded by the CHRNA7 gene are ligand-gated ion chan- nels directly related to memory and immunomodulation. Exons 5–7 in CHRNA7 can be duplicated and fused to exons A-E of FAR7a, resulting in a hybrid gene known as CHRFAM7A, unique to humans. Its product, denoted herein as Dupα7, is a truncated subunit where the N-terminal 146 residues of the ligand binding domain of the α7 receptor have been replaced by 27 residues from FAM7. Dupα7 negatively affects the functioning of α7 receptors associated with neurological disorders, including Alzheimer’s diseases and schizophrenia. However, the stoichiometry for the α7 nicotinic receptor containing dupα7 monomers remains unknown. In this work, we developed computational models Citation: Liu, D.; de Souza, J.V.; of all possible combinations of wild-type α7 and dupα7 pentamers and evaluated their stability via Ahmad, A.; Bronowska, A.K. atomistic molecular dynamics and coarse-grain simulations. We assessed the effect of dupα7 subunits Structure, Dynamics, and Ligand on the Ca2+ conductance using free energy calculations.
    [Show full text]
  • A Human-Specific A7-Nicotinic Acetylcholine Receptor Gene In
    A Human-Specific α7-Nicotinic Acetylcholine Receptor Gene in Human Leukocytes: Identification, Regulation and the Consequences of CHRFAM7A Expression Todd W Costantini,1* Xitong Dang,1,2* Maryana V Yurchyshyna,1 Raul Coimbra,1 Brian P Eliceiri,1 and Andrew Baird1 1Department of Surgery, University of California San Diego Health Sciences, San Diego, California, United States of America; and 2Cardiovascular Research Center, Luzhou Medical College, Luzhou, Sichuan, China The human genome contains a variant form of the α7-nicotinic acetylcholine receptor (α7nAChR) gene that is uniquely human. This CHRFAM7A gene arose during human speciation and recent data suggests that its expression alters ligand tropism of the normally homopentameric human α7-AChR ligand-gated cell surface ion channel that is found on the surface of many dif- ferent cell types. To understand its possible significance in regulating inflammation in humans, we investigated its expression in nor- mal human leukocytes and leukocyte cell lines, compared CHRFAM7A expression to that of the CHRNA7 gene, mapped its pro- moter and characterized the effects of stable CHRFAM7A overexpression. We report here that CHRFAM7A is highly expressed in human leukocytes but that the levels of both CHRFAM7A and CHRNA7 mRNAs were independent and varied widely. To this end, mapping of the CHRFAM7A promoter in its 5′-untranslated region (UTR) identified a unique 1-kb sequence that independently reg- ulates CHRFAM7A gene expression. Because overexpression of CHRFAM7A in THP1 cells altered the cell phenotype and modified the expression of genes associated with focal adhesion (for example, FAK, P13K, Akt, rho, GEF, Elk1, CycD), leukocyte transepithe- lial migration (Nox, ITG, MMPs, PKC) and cancer (kit, kitL, ras, cFos cyclinD1, Frizzled and GPCR), we conclude that CHRFAM7A is bi- ologically active.
    [Show full text]
  • Supplementary Table 1 Double Treatment Vs Single Treatment
    Supplementary table 1 Double treatment vs single treatment Probe ID Symbol Gene name P value Fold change TC0500007292.hg.1 NIM1K NIM1 serine/threonine protein kinase 1.05E-04 5.02 HTA2-neg-47424007_st NA NA 3.44E-03 4.11 HTA2-pos-3475282_st NA NA 3.30E-03 3.24 TC0X00007013.hg.1 MPC1L mitochondrial pyruvate carrier 1-like 5.22E-03 3.21 TC0200010447.hg.1 CASP8 caspase 8, apoptosis-related cysteine peptidase 3.54E-03 2.46 TC0400008390.hg.1 LRIT3 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 1.86E-03 2.41 TC1700011905.hg.1 DNAH17 dynein, axonemal, heavy chain 17 1.81E-04 2.40 TC0600012064.hg.1 GCM1 glial cells missing homolog 1 (Drosophila) 2.81E-03 2.39 TC0100015789.hg.1 POGZ Transcript Identified by AceView, Entrez Gene ID(s) 23126 3.64E-04 2.38 TC1300010039.hg.1 NEK5 NIMA-related kinase 5 3.39E-03 2.36 TC0900008222.hg.1 STX17 syntaxin 17 1.08E-03 2.29 TC1700012355.hg.1 KRBA2 KRAB-A domain containing 2 5.98E-03 2.28 HTA2-neg-47424044_st NA NA 5.94E-03 2.24 HTA2-neg-47424360_st NA NA 2.12E-03 2.22 TC0800010802.hg.1 C8orf89 chromosome 8 open reading frame 89 6.51E-04 2.20 TC1500010745.hg.1 POLR2M polymerase (RNA) II (DNA directed) polypeptide M 5.19E-03 2.20 TC1500007409.hg.1 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 6.48E-03 2.17 TC2200007132.hg.1 RFPL3 ret finger protein-like 3 5.91E-05 2.17 HTA2-neg-47424024_st NA NA 2.45E-03 2.16 TC0200010474.hg.1 KIAA2012 KIAA2012 5.20E-03 2.16 TC1100007216.hg.1 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 7.43E-03 2.15 TC0400012977.hg.1 SH3D19
    [Show full text]